BRAF/MEK抑制对携带BRAFV600E突变的上皮样胶质母细胞瘤的影响：一例报告及文献综述
Effect of BRAF/MEK Inhibition on Epithelioid Glioblastoma with BRAFV600E Mutation: a Case Report and Review of the Literature.
作者信息
Li Yan, Yang Shoubo, Hao Chengcheng, Chen Janxin, Li Shan, Kang Zhuang, Kang Xun, Zhang Hongmei, Li Wenbin
出版信息
Clin Lab. 2020 Aug 1;66(8). doi: 10.7754/Clin.Lab.2020.191134.
BACKGROUND
To explore the effect of BRAF inhibitor on epithelioid glioblastoma (Ep-GBM) with BRAFV600E mutation.
METHODS
A patient of Ep-GBM with BRAFV600E mutation underwent BRAF inhibition therapy. The rationale behind combined BRAF and MEK inhibition in Ep-GBM was reviewed.
RESULTS
Vemurafenib can initially inhibit the progression of Ep-GBM with BRAFV600E mutation. However, the tumor may become resistant to vemurafenib and then progress.
CONCLUSIONS
BRAF inhibition therapy can inhibit the progression of Ep-GBM with BRAFV600E mutation, but the subsequent resistance development leads to a poor outcome.
背景
探讨BRAF抑制剂对具有BRAFV600E突变的上皮样胶质母细胞瘤（Ep-GBM）的作用。
方法
一名具有BRAFV600E突变的Ep-GBM患者接受了BRAF抑制治疗。回顾了在Ep-GBM中联合BRAF和MEK抑制的理论依据。
结果
维莫非尼最初可抑制具有BRAFV600E突变的Ep-GBM的进展。然而，肿瘤可能会对维莫非尼产生耐药性，随后进展。
结论
BRAF抑制治疗可抑制具有BRAFV600E突变的Ep-GBM的进展，但随后出现的耐药性导致预后不良。
Zotero 插件